1
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Generalized morphea following the COVID vaccine: A series of two patients and a bibliographic review

      brief-report

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The appearance of morphea after vaccination has been reported to date as single and deep lesions that appear exactly at the site of the skin puncture. It was therefore postulated that the origin could be the trauma related to the injection. The aim of this article is to review the various hypotheses offered in the published literature about generalized morphea following vaccination. We present two cases of generalized morphea after COVID‐19 vaccination and review the published literature on immune‐related cutaneous reactions. As previously reported, antigenic cross‐reactivity between vaccine spike proteins and human tissues could cause certain immune‐mediated diseases, including generalized morphea. Herein we report two cases of generalized morphea probably induced by the COVID‐19 vaccine, given the temporal relationship with its administration. In summary, environmental factors such as vaccination against SARS‐COV‐2 could induce an immune system dysregulation, which would have an important role in the pathogenesis of morphea. We present two cases of generalized morphea probably induced by the COVID‐19 vaccine, given the time elapsed between vaccination and the onset of the skin lesions.

          Related collections

          Most cited references13

          • Record: found
          • Abstract: found
          • Article: not found

          Cutaneous Reactions Reported after Moderna and Pfizer COVID-19 Vaccination: A Registry-Based Study of 414 Cases

          Background Cutaneous reactions after mRNA-based COVID-19 vaccines have been reported but are not well characterized. Objective To evaluate morphology and timing of cutaneous reactions after mRNA COVID-19 vaccines. Methods A provider-facing registry-based study collected cases of cutaneous manifestations after COVID-19 vaccination. Results From December 2020-February 2021, we recorded 414 cutaneous reactions to mRNA COVID-19 vaccines from Moderna (83%) and Pfizer (17%). Delayed large local reactions were most common, followed by local injection site reactions, urticarial eruptions, and morbilliform eruptions. Forty-three percent of patients with first dose reactions experienced second dose recurrence. Limitations Registry analysis does not measure incidence. Morphologic misclassification is possible. Conclusion We report a spectrum of cutaneous reactions after COVID-19 mRNA vaccines. Most patients with first dose reactions did not develop a second dose reaction, and no patients in the registry developed serious adverse events after the first or second dose. These data provide reassurance to patients and providers.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates

            Understanding immune responses to severe acute respiratory syndrome coronavirus 2 is crucial to understanding disease pathogenesis and the usefulness of bridge therapies, such as hyperimmune globulin and convalescent human plasma, and to developing vaccines, antivirals, and monoclonal antibodies. A mere 11 months ago, the canvas we call COVID-19 was blank. Scientists around the world have worked collaboratively to fill in this blank canvas. In this Review, we discuss what is currently known about human humoral and cellular immune responses to severe acute respiratory syndrome coronavirus 2 and relate this knowledge to the COVID-19 vaccines currently in phase 3 clinical trials.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found

              Cutaneous reactions after SARS‐COV‐2 vaccination: A cross‐sectional Spanish nationwide study of 405 cases

              SUMMARY Background Cutaneous reactions after SARS‐CoV‐2 vaccines are poorly characterized. Objectives: The primary objective was to describe and classify cutaneous reactions after SARS‐CoV‐2 vaccination. Methods A nationwide Spanish cross‐sectional study was conducted. We included patients with cutaneous reactions within 21 days after any dose of the approved vaccines at the time of the study. After a face‐to‐face visit with a dermatologist, information on cutaneous reactions was collected through an online professional survey and clinical photographs were sent by email. Investigators searched for consensus on clinical patterns and classification. Results From February 16 to May 15, 2021, we collected 405 reactions after vaccination with the BNT162b2 (Pfizer‐BioNTech, 40.2%), mRNA‐1273 (Moderna, 36.3%) and AZD1222 (AstraZeneca, 23.5%) vaccines. The mean patient age was 50.7 years and 80.2% were female. Cutaneous reactions were classified as: injection‐site (COVID‐ARM, 32.1%), urticaria (14.6%), morbilliform (8.9%), papulovesicular (6.4%), pityriasis rosea‐like (4.9%) and purpuric (4%) reactions. Varicella zoster and herpes simplex virus reactivations accounted for 13.8% of reactions. The COVID‐ARM was almost exclusive to women (95.4%). The most reported reaction in each vaccine group were COVID‐ARM (mRNA‐1273, Moderna, 61.9%), varicella zoster virus reactivation (BNT162b2, Pfizer‐BioNTech, 17.2%), and urticaria (AZD1222, AstraZeneca, 21.1%). Most reactions to the mRNA‐1273 (Moderna) vaccine were described in women (90.5%). Eighty reactions (21%) were classified as severe/very severe and 81% required treatment. Conclusions Cutaneous reactions after SARS‐CoV‐2 vaccination are heterogeneous. Most are mild‐to‐moderate and self‐limiting, although severe/very severe reactions are reported. Knowledge of these reactions during mass vaccination may help healthcare professionals and reassure patients.
                Bookmark

                Author and article information

                Contributors
                nrodriguezga@unav.es
                Journal
                Dermatol Ther
                Dermatol Ther
                10.1111/(ISSN)1529-8019
                DTH
                Dermatologic Therapy
                John Wiley & Sons, Inc. (Hoboken, USA )
                1396-0296
                1529-8019
                20 July 2022
                20 July 2022
                : e15709
                Affiliations
                [ 1 ] Department of Dermatology University Clinic of Navarra, School of Medicine, University of Navarra Pamplona Spain
                Author notes
                [*] [* ] Correspondence

                Nuria Rodríguez‐Garijo, Department of Dermatology, University Clinic of Navarra, School of Medicine, University of Navarra, Avda. Pio XII, 36, 31008 Pamplona, Spain.

                Email: nrodriguezga@ 123456unav.es

                Author information
                https://orcid.org/0000-0002-8372-5044
                https://orcid.org/0000-0002-0359-3222
                https://orcid.org/0000-0001-9342-9698
                Article
                DTH15709
                10.1111/dth.15709
                9349378
                35811413
                bfd7ab70-f54c-4130-8736-37eacec04275
                © 2022 The Authors. Dermatologic Therapy published by Wiley Periodicals LLC.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                : 13 June 2022
                : 25 March 2022
                : 26 June 2022
                Page count
                Figures: 2, Tables: 0, Pages: 4, Words: 2093
                Categories
                Short Report
                Short Reports
                Custom metadata
                2.0
                corrected-proof
                Converter:WILEY_ML3GV2_TO_JATSPMC version:6.1.7 mode:remove_FC converted:04.08.2022

                covid,cross‐reactivity,immunorelated,morphea,vaccination
                covid, cross‐reactivity, immunorelated, morphea, vaccination

                Comments

                Comment on this article